The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Lazaros J. Lekakis
No Relationships to Disclose
 
Herbert Eradat
Honoraria - Abbvie; BeiGene; Genentech; Incyte; MorphoSys; Pharmacyclics
Consulting or Advisory Role - Abbvie; BeiGene; Genentech; Incyte; MorphoSys
Speakers' Bureau - Abbvie; BeiGene; Genentech; Incyte; MorphoSys
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BeiGene; BMSi; Celgene; Genentech; Gilead Sciences; Incyte; Juno Therapeutics; Kite, a Gilead Company; MorphoSys; Pharmacyclics
 
Javier Munoz
Honoraria - Curio Science; Kyowa Hakko Kirin; OncView; Physicans' Education Resource; Seagen; Targeted Oncology
Consulting or Advisory Role - ADC Therapeutics; Alexion Pharmaceuticals; Aurobindo; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Fosun Kite; Genentech; Genmab; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Seagen; Secura Bio; SERVIER; TG Therapeutics; Zodiac Pharma
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Michael Timothy Tees
No Relationships to Disclose
 
Sven de Vos
No Relationships to Disclose
 
Rajneesh Nath
Consulting or Advisory Role - Incyte
 
Don A. Stevens
No Relationships to Disclose
 
Shahbaz Malik
Research Funding - Alimera Sciences (Inst); Takeda (Inst)
 
Leslie Popplewell
Honoraria - ADC Therapeutics; Kite, a Gilead company
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Caribou Biosciences; crispr therapeutics; Gamida Cell; Genentech; Genmab; Incyte; Kite/Gilead; MorphoSys; Myeloid Therapeutics; Novartis; Omeros; Puma Biotechnology (I); Sanofi; Seagen; Verastem
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
Olalekan O. Oluwole
Consulting or Advisory Role - ADC Therapeutics; Curio Science; Epizyme; Gilead Sciences; Kite/Gilead; Legend Biotech; Nektar; Novartis; Syncopation Life Sciences
Research Funding - Kite, a Gilead company (Inst)
 
Miguel-Angel Perales
Stock and Other Ownership Interests - NexImmune
Honoraria - MorphoSys
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Cidara Therapeutics; Incyte; Kite/Gilead; Medigene; Merck; MolMed; Nektar; NexImmune; Novartis; Omeros; Servier/Pfizer; Vor Biopharma
Research Funding - Incyte (Inst); Kite, a Gilead company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst)
 
David Bernard Miklos
Honoraria - fosun Kite Biotechnology; Janssen
Consulting or Advisory Role - Adaptive Biotechnologies; Allogene Therapeutics; Caribou Biosciences; Janssen; Kite, a Gilead company
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
 
Paul Fisher
No Relationships to Disclose
 
Lovely Goyal
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
 
Gregory Kaufman
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
 
Kazuharu Kai
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
 
Arun Balakumaran
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
Patents, Royalties, Other Intellectual Property - Allogene Therapeutics
 
Sattva Swarup Neelapu
Stock and Other Ownership Interests - Longbow Immunotherapy
Honoraria - MJH Life Sciences; Peerview
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Astellas Pharma; Athenex; Bluebird Bio; Bristol-Myers Squibb; Caribou Biosciences; Chimagen Biosciences; Fosun Kite; Gilead Sciences; ImmunoACT; Incyte; Janssen medical Affairs; Kite, a Gilead company; Morphosys; Orna Therapeutics; Sana Biotechnology; Sellas Life Sciences; Takeda
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Gilead Sciences; Kite, a Gilead company; Precision Biosciences
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy